ArticleEuropean journal of medical research2025
MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPolo-like kinase 1 (PLK1) functionally mediates tumorigenesis of pancreatic cancer (PC) and associates with its drug resistance to gemcitabine, but related inhibitor therapies were poorly explored. MLN0905 is a novel small molecule inhibitor targeting PLK1. Here we investigate the therapeutic capacity for gemcitabine-resistant pancreatic cancer and related molecular mechanism of MLN0905.
methodsThe inhibitory efficacy of MLN0905 on gemcitabine-resistant PC cell lines was assessed using cell viability assays, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), the colony formation assay, and flow cytometry detecting cell cycle or apoptosis. In addition, changes in the G2/M phase ratio were further analyzed. Cell cycle and apoptosis-related defects in MLN0905 treated PC cells were detected using western blot analysis. In addition, a subcutaneous tumor model of pancreatic cancer (PC) resistant to gemcitabine was established in vivo to investigate the inhibitory effect of MLN0905 in animal model and evaluate its safety to liver or kidney functions. Tumor volume, tumor weight, Ki67 expression, and the expression of cluster of differentiation 31 (CD31) were measured following the administration of MLN0905. Meanwhile, several detects for alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose (GLU) and creatinine (Cr) were also performed to further confirm the safety of MLN0905 in liver and kidney functions.
resultsExperiments related to cell viability demonstrated that MLN0905 inhibited cell proliferation, induced cell cycle arrest, and promoted apoptosis in gemcitabine-resistant PC cell lines. Mechanistically, the phosphorylation level of PLK1 gradually deceased with the increase of drug concentration, while the expression of PHH3 and γH2A.x increased. In vivo evaluation showed the effective inhibition of MLN0905 in tumor growth and its good security.
conclusionsOur research has indicated that MLN0905 interferes with cancer cell DNA replication by specifically targeting PLK1, leading to cell cycle arrest and apoptosis, thereby preventing tumor growth and effectively eradicating gemcitabine-resistant pancreatic cancer cells, demonstrating satisfactory safety in this study. This research provides a detailed analysis of the interactions between MLN0905, PLK1, and gemcitabine resistance in the progression of pancreatic cancer, offering new prospects and insights for overcoming gemcitabine resistance in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.